| Trial | Updated / Type |
Status | Phase | Were Results Reported |
Reported Actual Enrollment |
(MeSH) Terms |
Why Stopped
Limitations And Caveats |
Annotator decisions |
|---|---|---|---|---|---|---|---|---|
| NCT02983097 2009-010824-25 Details | 2018-01-19 Interventional | 1/2 | 34 | Carboplatin Cytarabine Dexamethasone Lenalidomide Rituximab Aggression Burkitt Lymphom… Lymphoma Lymphoma, B-Cel… Lymphoma, Large… Lymphoma, Mantl… Lymphoma, Non-H… Aggressive Marg… Burkitt Lymphom… Diffuse Large B… Follicular Lymp… Mantle Cell Lym… | Phase II: no scientific interests are given anymore - | |||
| NCT00126568 Details | 2018-01-19 Interventional | 2 | 20 | Sorafenib Thyroid Carcino… Thyroid Disease… Thyroid Neoplas… Anaplastic Thyr… Recurrent Thyro… | - The study met the pre-specified criteria for enrollment of all planned 32 patients. However due to poor accrual the study was halted. | |||
| NCT00864175 Details | 2018-01-18 Interventional | 1/2 | 68 | Docetaxel Trastuzumab Breast Neoplasm… Breast Cancer | Incyte suspended development of the compound. - | |||
| NCT03401606 Details | 2018-01-17 Interventional | 4 | 98 | Dexmedetomidine Remifentanil Cataract Failed Consciou… | a respiratory depression in remifentanyl group - | |||
| NCT02297490 Details | 2018-01-17 Interventional | 2 | 158 | Immunomodulatin… Allergic Rhinoc… Healthy Volunte… | The study was terminated due to the interim Analysis results indicating a weaker correlation
than anticipated and reported by other study groups. - | |||
| NCT02155309 Details | 2018-01-17 Interventional | 2/3 | 63 | Butylscopolammo… Scopolamine Motion Sickness | Business reason - | |||
| NCT01132521 Details | 2018-01-17 Interventional | 4 | [3 Refs] | 252 | Trypsin Inhibit… Urinastatin Pancreatitis | Revised project - | ||
| NCT00303888 Details | 2018-01-17 Interventional | 1 | 31 | Docetaxel Carcinoma, Ovar… Fallopian Tube … Peritoneal Neop… Fallopian Tube … Ovarian Cancer Primary Periton… | - - | |||
| NCT03108729 Details | 2018-01-16 Interventional | 3 | 0 | Eslicarbazepine… Epilepsy | The study was not withdrawn for safety reasons. The sponsor received approval for the treatment
of partial-onset seizures in patients 4 years of age and older - | |||
| NCT02479490 Details | 2018-01-16 Interventional | 2 | 8 | Everolimus Prednisone Carcinoma, Rena… Kidney Neoplasm… Metastatic Rena… | - - | |||
| NCT02968121 Details | 2018-01-12 Interventional | 1 | 22 | Brexpiprazole Schizophrenia | Part A of study was completed per protocol. Conduct of Part B of the study (confirmatory phase)
was not necessary. - | |||
| NCT03005184 Details | 2018-01-11 Interventional | 2 | 0 | Enalapril Icatibant Sacubitril and … Valsartan Heart Failure Heart Failure N… Heart Failure N… Heart Failure N… | Study is being redesigned and submitted as a new study. - | |||
| NCT03094468 Details | 2018-01-10 Interventional | 3 | 0 | Terbinafine Onychomycosis Onychomycosis o… | Project development priorities changed - | |||
| NCT03079973 NCT03209388 Details | 2018-01-10 Interventional | 3 | 0 | Calcipotriene Psoriasis Nail Psoriasis | Project development priorities changed. - | |||
| NCT02908165 Details | 2018-01-10 Interventional | 2 | 0 | Chlorotrianisen… Sorafenib Carcinoma, Hepa… Hepatocellular … | A future study will be taking place using the same patient population. - | |||
| NCT00470548 Details | 2018-01-10 Interventional | 1/2 | [1 Refs] | 49 | Albumin-Bound P… Paclitaxel Pemetrexed Breast Neoplasm… Lung Neoplasms Breast Cancer Lung Cancer Unspecified Adu… | Practice patterns with pemetrexed have evolved. The phase II portion accrued 37 patients before early closure due to increasing the first-line pemetrexed/platinum doublet use in non-squamous NSCLC. | ||
| NCT03343678 2014-004957-16 Details | 2018-01-09 Interventional | 1 | 0 | BI 836826 Venetoclax Leukemia Leukemia, Lymph… Leukemia, Lymph… | Company strategic decision - | |||
| NCT02569437 Details | 2018-01-09 Interventional | 2 | 49 | Doxycycline Fluticasone Methylprednisol… Methylprednisol… Methylprednisol… Prednisolone Prednisolone ac… Prednisolone he… Prednisolone ph… Nasal Polyps Polyps Rhinosinusitis Polyp of Nasal … | A high percentage of patients were dropping out of the study and were not able to complete the
protocol. Power not adequate and study is at risk for a Type II error - study was ended prior to complete sample size accrual. Study recruited high percentage of severe disease patients, thus did not accurately represent moderate disease patients. | |||
| NCT01261299 Details | 2018-01-09 Interventional | 1 | 21 | Carboplatin Carcinoma, Non-… Neoplasms Urinary Bladder… | Contract ended - | |||
| NCT03238638 Details | 2018-01-04 Interventional | 2 | 0 | Pembrolizumab Head and Neck N… Head and Neck C… | PI did not attempt to open the study. - |